ArticlePloS one2013

Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).

Samuel Q Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.